Format

Send to

Choose Destination
Haematologica. 2019 May;104(5):864-867. doi: 10.3324/haematol.2018.214536.

Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?

Author information

1
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
2
Division of Hematopathology, Department of Pathology, University of Virginia, Charlottsville, VA, USA.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center